A-Prof Greg King is a respiratory physician researcher whose studies are to define the mechanisms by which diseases, such as asthma and COPD occur. He has developed novel tools to measure lung disease, particularly complex lung function testing and lung imaging.
This program of work focuses on smoking related lung diseases including chronic bronchitis and emphysema, and lung cancer, as well as diseases affecting the blood vessels in the lungs. The work includes basic cell biology and human clinical trials.There is a high likelihood that new approaches to treating lung disease will emerge.
Airway Inflammometry For Asthma And COPD: Practitioner Fellowship Peter G Gibson
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Asthma and chronic obstructive pulmonary disease will receive the benefits of personalized medicine with this Fellowship funding. Dr Gibson, an international leader in this field, has identified key biomarkers that will allow treatments to be rationalized based on the underlying disease mechanisms. This research will translate the benefits on modern technology and apply these to individualized care for people with asthma and COPD, who can expect fewer lung attacks and better quality of life.
Stephen Stick Practitioner Fellowship In Paediatric Respiratory Medicine
Funder
National Health and Medical Research Council
Funding Amount
$542,272.00
Summary
Fellowship will facilitate the further study of mechanisms of chronic childhood respiratory disease and strategies for intervention to reduce morbidity and improve quality of life for patients and families.
Professor Stick is a career clinician researcher in Paediatric Respiratory Medicine. He has established worl-leading research teams focused on respiratory diseases in young children such as cystic fibrosis and asthma. He has has developed innovative methods to study early childhood respiratory diseases and has been responsible for training scores of clinicians and scientists in the field. He has received national and international awards in recognition of his achievements.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$585,269.00
Summary
This Fellowship will allow Professor Lloyd to continue clinical and laboratory research in two areas: firstly, in relation to prevention of transmission of hepatitis C infection, and scale up of antiviral treatments, particularly amongst prisoners. Secondly, in studies investigating the biological basis of chronic fatigue states following acute infection or cancer treatment, and also in development of effective treatment for chronic fatigue states.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$532,630.00
Summary
Professor Lloyd will continue studies of the factors which lead to varied clinical outcomes from common infectious diseases. The outcomes include chronic or persistent illness, rather than prompt recovery. The factors being studied include aspects of the microbes causing the infection; and aspects of the individual suffering from infection, including genetic make-up, immune defences, and treatment responses. The infections studied include common "flu-like" illnesses, as well as hepatitis C.
This Practitioner Fellowship will aim to improve outcomes in people with lung cancer. The clinical studies will focus on: 1. Using low dose CT scans to detect lung cancer at a very early stage. 2. Molecular tests to diagnose lung cancer earlier, and provide information that will be useful for deciding treatment 3. Using advanced techniques to diagnose small opacities in the lung
Understanding Early Life Risk Factors For Inflammation In The Rising Predisposition For NCDs
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
In 2011 the UN General Assembly identified the rise in non-communicable diseases (NCDs) as a major global threat, and prioritized preventive strategies against diseases like obesity, diabetes, heart disease, allergy and asthma. Common risk factors for these inflammatory diseases begin early in life, the most logical time for prevention. Our international interdisciplinary network aims to improve health and prevent NCDs by early interventions that reduce inflammation over the life-course.
Chronic myeloid leukaemia was almost always fatal before the development of imatinib a decade ago, the first tyrosine kinase inhibitor (TKI) developed to treat a human cancer. There are now more potent TKIs that are effective in cases of resistance to imatinib. The challenge now is to optimise the achievement of remissions using these drugs and convert CML into a curable condition. This will be the focus of my NHMRC Practitioner Fellowship over the next 5 years.